Development of a sensitive and stable chemiluminescent immunoassay for detection of birch pollen allergic specific IgE based on recombinant Bet v1 protein

2021 ◽  
pp. 113040
Author(s):  
Jinyan Gao ◽  
Rongfeng Cai ◽  
Nandi Zhou
Keyword(s):  
Birch Pollen ◽  
Specific Ige ◽  
Chemiluminescent Immunoassay ◽  
Bet V1

Potential Differences between Local and Systemic Allergic Rhinitis Induced by Birch Pollen

2020 ◽  
Vol 181 (11) ◽  
pp. 831-838
Author(s):  
Andrzej Bozek ◽  
Jolanta Zalejska Fiolka ◽  
Anna Krajewska Wojtys ◽  
Beata Galuszka ◽  
Anna Cudak
Keyword(s):  
Allergic Rhinitis ◽  
Birch Pollen ◽  
Provocation Test ◽  
Basophil Activation Test ◽  
Specific Ige ◽  
Immunological Parameters ◽  
Local Allergic Rhinitis ◽  
Before And After ◽  
Intermittent Allergic Rhinitis ◽  
Bet V1

<b><i>Introduction:</i></b> Different endotypes of rhinitis are known, but its pathomechanism has not been conclusively established. For example, the precise difference between systemic allergic rhinitis (SAR) and local allergic rhinitis (LAR) is still being checked. Comparison of patients with LAR and with allergies to birch of those with intermittent allergic rhinitis, same allergy, or with non-allergic rhinitis (NAR) was the purpose of this study. <b><i>Methods:</i></b> Twenty-six patients with LAR, 18 with SAR and allergy to birch, and 21 with NAR were included. Patients who met the inclusion criteria were selected to undergo the following procedures at baseline: medical examinations, nasal provocation test (NPT), detection of nasal-specific IgE to birch as well as basophil activation test (BAT). All immunological parameters were detected before and after NPT. <b><i>Results:</i></b> Concentration of nasal IgE to Bet v1 increased comparably in the LAR and SAR groups after NPT to birch as follows: in 21 (81%) patients with LAR, 14 (78%) with SAR, and in everyone in the NAR group. Serum concentration of allergen-specific IgE to Bet v1 increased significantly from a median of 20.7 (25–75% interval: 11.2–35.6) IU/mL to 29.9 (13.6–44.1) (<i>p</i> = 0.028) after NPT in patients with SAR. Allergen-specific IgE to Bet v1 was absent in all patients with LAR and NAR before and after NPT. BAT with Bet v1 was positive in 22 (85%) patients with LAR, in 14 (78%) with SAR, and 2 (9.5%) with NAR. <b><i>Conclusion:</i></b> These obtained data suggest there are no potential mechanisms that could explain LAR compared to SAR.

Quality and potency profile of eight recombinant isoallergens, largely mimicking total Bet v 1‐specific IgE binding of birch pollen

2019 ◽  
Vol 49 (5) ◽  
pp. 712-723 ◽  
Author(s):  
Christian Seutter von Loetzen ◽  
Andreas Reuter ◽  
Jelena Spiric ◽  
Thomas Schulenborg ◽  
Iris Bellinghausen ◽  
...  
Keyword(s):  
Birch Pollen ◽  
Specific Ige ◽  
Bet V 1 ◽  
Ige Binding

scholarly journals Agaricus blazei-Based Mushroom Extract Supplementation to Birch Allergic Blood Donors: A Randomized Clinical Trial

Nutrients ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 2339 ◽  
Author(s):  
Faiza Mahmood ◽  
Geir Hetland ◽  
Ivo Nentwich ◽  
Mohammad Reza Mirlashari ◽  
Reza Ghiasvand ◽  
...  
Keyword(s):  
Placebo Group ◽  
Pollen Season ◽  
Blood Donors ◽  
Birch Pollen ◽  
Specific Ige ◽  
Basophil Activation ◽  
Pollen Extract ◽  
Agaricus Blazei ◽  
Oral Supplementation ◽  
Bet V 1

Since Agaricus blazei Murill (AbM) extract reduced specific IgE and ameliorated a skewed Th1/Th2 balance in a mouse allergy model, it was tested in blood donors with self-reported, IgE-positive, birch pollen allergy and/or asthma. Sixty recruited donors were randomized in a placebo-controlled, double-blinded study with pre-seasonal, 7-week, oral supplementation with the AbM-based extract AndosanTM. Before and after the pollen season, questionnaires were answered for allergic rhino-conjunctivitis, asthma, and medication; serum IgE was measured, and Bet v 1-induced basophil activation was determined by CD63 expression. The reported general allergy and asthma symptoms and medication were significantly reduced in the AbM compared to the placebo group during pollen season. During the season, there was significant reduction in specific IgE anti-Bet v 1 and anti-t3 (birch pollen extract) levels in the AbM compared with the placebo group. While the maximal allergen concentrations needed for eliciting basophil activation before the season, changed significantly in the placebo group to lower concentrations (i.e., enhanced sensitization) after the season, these concentrations remained similar in the AndosanTM AbM extract group. Hence, the prophylactic effect of oral supplementation before the season with the AbM-based AndosanTM extract on aeroallergen-induced allergy was associated with reduced specific IgE levels during the season and basophils becoming less sensitive to allergen activation.

scholarly journals Different Development Forms of Local Allergic Rhinitis towards Birch

2020 ◽  
Vol 2020 ◽  
pp. 1-9 ◽  
Author(s):  
Andrzej Bozek ◽  
Janne Winterstein ◽  
Beata Galuszka ◽  
Jerzy Jarzab
Keyword(s):  
Allergic Rhinitis ◽  
Outcome Measurement ◽  
Birch Pollen ◽  
Specific Ige ◽  
Active Group ◽  
Placebo Control ◽  
Double Blind ◽  
Local Allergic Rhinitis ◽  
The Mean ◽  
The Impact

Background. Efficacy of allergen immunotherapy (AIT) in local allergic rhinitis (LAR) is a new subject of research. The presence of asthmatic symptoms in patients with LAR in the context of AIT is unexplored. Objective. The efficacy and safety of AIT in patients with LAR towards birch pollen were investigated. The possibility of concomitant local allergic asthma in studied patients and the impact of AIT on it were examined. Methods. 36 patients with LAR towards birch were included in three years of AIT in a double-blind, placebo-control study. Primary outcome measurement was the mean changes in the combined symptom and medication scores (CSMSs) after AIT, and the second is the changes in the quality of life (QoL). Skin prick tests, serum, nasal allergen-specific IgE to birch, nasal and bronchial provocation challenge tests with birch allergen, methacholine tests, and spirometry were carried out at baseline and after AIT. Results. Mean CSMSs of three years of AIT were significantly decreased in the active group from 5.88 (range: 4.11-9.01) to 1.98 (range: 1.22-4.51; p<0.05). After three years of AIT, there was a significant increase of toleration for birch allergen from the mean concentration of 6250±1200 SQ-U/ml up to 45000±2500 SQ-U/ml (p=0.02) during repeated nasal challenges. 16 patients with LAR had the positive results of methacholine tests, and 11 of them had a positive bronchial challenge to birch allergen. After AIT, the significant decrease of bronchial responsiveness to birch allergen in 5 from 7 patients was confirmed (p=0.03). QoL assessed by the use of the RQLQ score was improved after AIT from 1.84 (95% CI: 1.53-1.97) to 1.45 (95% CI: 1.32-1.62) score in the active group after three years of AIT therapy (p=0.03). Conclusion. AIT to birch can be useful and safe in a patient with local allergic rhinitis and also with concomitant asthmatic symptoms. Further studies are needed.

scholarly journals Component-Resolved Diagnosis in Pediatrics

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Ole D. Wolthers
Keyword(s):  
Allergic Disease ◽  
Birch Pollen ◽  
Pollen Allergy ◽  
Cost Benefit ◽  
Specific Ige ◽  
Component Resolved Diagnosis ◽  
Birch Pollen Allergy ◽  
Traditional Work ◽  
Diagnostic Work ◽  
Work Up

Component resolved diagnosis is a new concept in the investigation of pediatric allergic disease. The aim of the present paper is to review the available data on component resolved diagnosis with respect to implications for investigation of children with allergic disease. In most conditions head-to-head comparisons of component resolved diagnosis with traditional IgE testing have not been performed. Rather than alternatives the molecular methods should be seen as adjuncts to the cheaper traditional specific IgE tests. It may be appropriate to determine IgE antibodies to components as part of the diagnostic work-up in selected cases of peanut and birch pollen allergy and in hymenoptera allergy. However, cost benefit analyses of component resolved diagnosis compared with traditional work-up of allergy are needed. Prospectively planned protocols for assessment of the extent to which component resolved diagnosis may be able to improve the selection of children to immunotherapy and, thus, the efficacy of immunotherapy, are needed. Finally, studies of component resolved diagnosis with microarray technology in screening panels with hundreds of components should be undertaken before it can be determined to which extent such panel screening, if at all, may be helpful in children.

Sign in / Sign up

Export Citation Format

Share Document